Timothy Chao, Zi-Xuan Wang, Wilbur B Bowne, Clifford J Yudkoff, Ava Torjani, Vishal Swaminathan, Taylor R Kavanagh, Austin Roadarmel, Cyrus J Sholevar, Shawnna Cannaday, Geoffrey Krampitz, Tingting Zhan, Eliyahu Gorgov, Avinoam Nevler, Harish Lavu, Charles J Yeo, Stephen C Peiper, Wei Jiang
CONTEXT.—: Mutant KRAS is the main oncogenic driver in pancreatic ductal adenocarcinomas (PDACs). However, the clinical and phenotypic implications of harboring different mutant KRAS alleles remain poorly understood. OBJECTIVE.—: To characterize the potential morphologic and clinical outcome differences in PDACs harboring distinct mutant KRAS alleles. DESIGN.—: Cohort 1 consisted of 127 primary conventional PDACs with no neoadjuvant therapy, excluding colloid/mucinous, adenosquamous, undifferentiated, and intraductal papillary mucinous neoplasm-associated carcinomas, for which an in-house 42-gene mutational panel had been performed...
March 8, 2024: Archives of Pathology & Laboratory Medicine